Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Share News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.50
Ask: 3.80
Change: 0.00 (0.00%)
Spread: 0.30 (8.571%)
Open: 3.65
High: 3.65
Low: 3.65
Prev. Close: 3.65
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends

Thu, 07th Sep 2023 11:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Angle PLC, up 21% 13.87p, 120-month range pence, 12-month range 10.65p-75.25p. The medical diagnostics company says revenue in the first half trebles to GBP1.2 million from GBP419,000 a year before, as pretax loss widens to GBP10.6 million from GBP10.5 million. Says its pipeline for products and services businesses is building well, and momentum is expected to continue into the second half. Annual revenue is expected to be in line with market expectations. Also notes headline results for its major clinical studies are expected by the end of the year, and will demonstrate the key clinical applications of its liquid biopsy system Parasortix in patient care. Cash will be ahead of forecasts at the end of the year, thanks to careful control of costs and the deferral of some discretionary expenditure. This will extend the firm's cash runway into the first quarter of 2025, without affecting revenue in the next 24 months, Angle says. The stock is down 80% over the past 12 months, however.

----------

Directa Plus PLC, up 20% at 52p, 12-month range 43p-108p. The graphene product maker's environmental services subsidiary Sectar SA signs three-year contract to process oily mills sludge with Liberty Galati, the largest integrated steel producer in Romania. Contract is worth a total of EUR5.5 million, with potential for further expansion up to a total of EUR8.0 million. Setcar will provide solutions for the treatment of oily mills scale produced in the manufacturing of steel. Directa says the contract would enable Setcar to expand further its waste treatment and disposal services for industrial pollutants and broaden the range of applications for the group's Grafysorber technology. CEO Giulio Cesareo says the contract is the largest to date and a "very exciting win". It is equivalent to the firm's entire turnover in 2020, he adds.

----------

AIM - LOSERS

----------

CVS Group PLC, down 27% at 1,524p, 12-month range 1,365p-2,226p. The veterinary services firm plunges as the UK competition regulator kicks off a probe into the vet sector. The Competition & Markets Authority is launching a review of the sector, looking at consumer experiences and vet business practices for household pets in the UK. It cites concerns that pet owners are not getting value for money, and the rising costs of pet care have risen faster than wider inflation. Pets at Home Group PLC shares are also down 9.5%, with the retailer also operating veterinary surgeries and practices. "The sell-off seen today could be an overreaction, although the CMA review looks to be wide-ranging. The problem for both businesses is the process is likely to be time-consuming and, with a further update not due until early 2024, it could weigh on both stocks for some time to come," says AJ Bell investment director Russ Mould.

----------

Polarean Imaging PLC, down 18% at 11.85p, 12-month range 10.41p-84.2p. The medical imaging technology developer withdraws its commercial targets, with its CEO of three months Christopher von Jako citing his experience that "early sales are often irregular and difficult to forecast" during the commercialisation process. "While I am confident in the demand for our product and its ability to gain commercial traction, we feel it is sensible to withdraw the previously stated commercial targets at this time. We will, however, be providing renewed guidance at a suitable time," he says. In the first half of 2023, revenue drops to USD142,384 from USD834,087 a year before, as pretax loss widens to USD7.4 million from USD6.9 million.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Apr 2024 20:16

TRADING UPDATES: Nexteq confident of meeting full-year expectations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 14:28

Polarean Imaging shares sink after announcing a costly strategic plan

(Alliance News) - Polarean Imaging PLC shares dropped on Thursday, after the company said it would need to find an additional USD10 million to finance its medium-term ambitions.

Read more
15 Jan 2024 11:21

IN BRIEF: Polarean Imaging strategic parter raises stake to above 10%

Polarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price.

Read more
7 Dec 2023 16:01

Polarean gets first de novo order for Xenoview polariser

(Sharecast News) - Lung-focussed MRI technology developer Polarean Imaging said in an update on Thursday that it has received its first de novo order for a new Xenoview polariser.

Read more
7 Dec 2023 12:14

IN BRIEF: Polarean shares jump on Xenoview polariser order

Polarean Imaging PLC - London-based medical imaging technology developer - Receives its first de novo order for a new Xenoview polariser from an unnamed "top-tier" academic medical centre located in the northeast of the US. Polarean says it continues to have positive meetings and is in active negotiations with additional academic medical centres. Xenoview is a hyperpolarised contrast agent for use with magnetic imaging for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. It was approved for use in the US last year.

Read more
7 Dec 2023 11:11

AIM WINNERS & LOSERS: Smart Metering accepts offer; order for Polarean

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
8 Sep 2023 14:12

Polarean Imaging enters strategic partnership with VIDA Diagnostics

(Sharecast News) - Advanced MRI technology specialist Polarean Imaging announced a strategic partnership with a clinical imaging intelligence company VIDA Diagnostics on Friday.

Read more
8 Sep 2023 10:27

Polarean Imaging partners with Vida Diagnostics on MRI solutions

(Alliance News) - Polarean Imaging PLC on Friday said that it has partnered with Vida Diagnostics Inc to work on advanced magnetic resonance imaging solutions for the lungs.

Read more
7 Sep 2023 14:26

TRADING UPDATES: Polarean withdraws commercial targets on revenue drop

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
5 Sep 2023 19:42

IN BRIEF: Polarean Imaging announces code price range for Xenoview

Polarean Imaging PLC - London-based medical imaging technology developer - Announces that following statement on August 29, the reimbursement code for the Polarean Xenoview technology has been assigned to a new technology ambulatory payment classification code which corresponds to a payment range of between USD1,201 to USD1,300 as part of the 2023 medicare hospital outpatient prospective payment system final rule. Notes the codes enables healthcare providers a path to bill for "magnetic resonance imaging with inhaled hyperpolarised xenon-129 contrast agent, chest, including preparation and administration of agent."

Read more
31 Aug 2023 15:52

UK earnings, trading statements calendar - next 7 days

Friday 1 September 
Diversified Energy Co PLCHalf Year Results
Monday 4 September 
Ashtead Technology Holdings PLCHalf Year Results
Belvoir Group PLCHalf Year Results
Tuesday 5 September 
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Blackbird PLCHalf Year Results
Craneware PLCFull Year Results
DS Smith PLCTrading Statement
Ecora Resources PLCHalf Year Results
Eurocell PLCHalf Year Results
Gamma Communications PLCHalf Year Results
GetBusy PLCHalf Year Results
Headlam Group PLCHalf Year Results
Johnson Service Group PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
Pebble Group PLCHalf Year Results
Shearwater Group PLCFull Year Results
SigmaRoc PLCHalf Year Results
STV Group PLCHalf Year Results
Tissue Regenix Group PLCHalf Year Results
Wednesday 6 September 
Apax Global Alpha LtdHalf Year Results
Ashmore Group PLCFull Year Results
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Darktrace PLCFull Year Results
Halfords Group PLCTrading Statement
Hochschild Mining PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Nexteq PLCHalf Year Results
Oxford Nanopore Technologies PLCHalf Year Results
Restaurant Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 7 September 
Angle PLCHalf Year Results
Beazley PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Currys PLCTrading Statement
Direct Line Insurance Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
Hilton Food Group PLCHalf Year Results
Inspecs Group PLCHalf Year Results
International Public Partnerships LtdHalf Year Results
Lords Group Trading PLCHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Playtech PLCHalf Year Results
Polarean Imaging PLCHalf Year Results
Safestore Holdings PLCTrading Statement
Synthomer PLCHalf Year Results
Vistry Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
29 Aug 2023 14:22

Polarean's Xenoview gets US reimbursement code

(Sharecast News) - Medical device developer Polarean Imaging announced on Tuesday that its Xenoview technology has been granted a new reimbursement code by the US Centers for Medicare and Medicaid Services (CMS).

Read more
29 Aug 2023 11:36

IN BRIEF: Polarean Imaging product cleared for US Medicare payments

Polarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean's Xenoview or 'xenon XE 129' magnetic resonance imaging technology. Code "enables healthcare providers a path to bill for 'magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent'." Polarean expects to be informed of the new code's payment level "in the coming weeks".

Read more
3 Aug 2023 11:31

IN BRIEF: Polarean hails US FDA approval on Philips MRI configuration

Polarean Imaging PLC - London-based medical imaging technology company - Receives 510(k) clearance from the US Food & Drug Administration for its specialised magnetic resonance imaging chest coil. The coil may now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 nuclei.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.